YAYuichiro Arima

Yuichiro Arima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuichiro Arima has a total of 333 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Amlodipine and nifedipine associations with B-type natriuretic peptide in women with hypertension and heart failure with preserved ejection fraction

    by Eisaku Harada, Toshihiro Yamada, Yuji Mizuno, Yuichiro Arima, Makoto Muta, Koichi Kikuta, Hirofumi Yasue

    Background: Calcium channel blockers (CCBs) are frequently prescribed to manage hypertension in patients with heart failure with preserved ejection fraction (HFpEF). However, whether individual dihydropyridine agents exert uniform class effects on myocardial wall stress remains unclear. Methods: This retrospective, single-center observational study analyzed 465 consecutive patients with hypertension and HFpEF (354 women and 111 men) evaluated at Kumamoto Kinoh Hospital between May 2012 and July 2018. Multivariable linear regression models assessed associations between individual dihydropyridine CCBs (amlodipine vs nifedipine) and plasma log-transformed B-type natriuretic peptide (lnBNP) levels. Results: In multiple imputation models among women, adjusted differences in lnBNP relative to no-CCB were 0.236 (95% CI, 0.031 to 0.441) for nifedipine and −0.118 (95% CI, −0.273 to 0.037) for amlodipine. Direct linear contrasts in women confirmed lower lnBNP levels with amlodipine than with nifedipine (adjusted difference, −0.355; 95% CI, −0.562 to −0.147). In men, the corresponding amlodipine-vs-nifedipine difference was −0.051 (95% CI, −0.697 to 0.595; P = .876). The formal sex-by-drug interaction contrast in complete-case analysis yielded an adjusted difference of −0.424 (95% CI, −1.055 to 0.208; P = .188), with male precision constrained by sample size (7 male nifedipine users). Conclusions: In women with hypertension and heart failure with preserved ejection fraction, amlodipine use was associated with lower adjusted ln(BNP) levels than nifedipine use. These observational findings challenge the assumption of an interchangeable dihydropyridine class effect on myocardial wall stress, suggesting that individual pharmacological profiles—rather than uniform class-level equivalence—warrant attention in clinical evaluations.

  • Open Access

    Suppressing glutamate dehydrogenase guides hematopoietic stem cell divisions into self-renewal

    by Michihiro Hashimoto, Michie Uchikawa, Yuichiro Arima, Akiyasu Iwase, Ayano Yahagi, Mizuki Ishimaru, Tomomasa Yokomizo, Ayako Nakamura-Ishizu, Yosuke Tanaka, Kenichi Miharada, et al.

    Hematopoietic stem cells (HSCs) self-renew to expand their pool but often differentiate upon division. Thus, it remains unclear how HSCs maintain their stemness during or after division. Here, we show that the suppression of glutamate dehydrogenase (Glud1), a key enzyme responsible for glutamate (Glu) catabolism, supports the maintenance of HSCs during division. We find that self-renewing mouse HSCs during hematopoietic regeneration exhibited lower intracellular Glu levels compared to HSCs differentiating during ex vivo culture. We therefore focus on the negative regulation of Glu catabolic reactions as a candidate factor to maintain HSCs during division, and find that treatment with the Glud1 inhibitor, R162, maintains a subset of HSCs that would otherwise differentiate during division under normal culture conditions. This treatment successfully results in an approximately 500-fold expansion of functional mouse HSCs that maintain expression pattern of conventional stem cell markers over a 30-day culture period. Importantly, this positive effect of Glud1 inhibition is independent of suppressing cell divisions and dependent on robust JAK2-STAT signaling. Overall, our findings propose that Glud1 inhibition, coupled with robust JAK2–STAT signaling, characterizes a functional HSC state during division, enabling ex vivo expansion of mouse HSCs under conventional culture conditions.

  • Open Access

    The Cyclin C-CDK8/19 Mediator kinase module controls PRCC-TFE3 driven senescence in renal epithelium and tumorigenesis in TFE3-RCC

    by Shoichiro Kuroda, Shintaro Funasaki, Hidekazu Nishizawa, Laura S. Schmidt, Ryoma Kurahashi, Takaaki Ito, Yuichiro Arima, Miwa Tanaka, Atsuya Kitada, Amy M. James, et al.

  • Open Access

    Hepatic Ketogenesis Attenuates Cardiac Hypertrophy via Metabolic Reprogramming

    by Toshihiro Yamada, Kei Morikawa, Akira Fujiyama, Takumi Nagakura, Yuqing Xu, Miho Kataoka, Terumasa Umemoto, Miki Bundo, Kazuya Iwamoto, Zeeshan Ahmed, et al.

    Background: Heart failure with preserved ejection fraction (HfpEF) is increasingly recognized as a multisystem disorder linked to the cardiovascular-kidney-metabolic (CKM) syndrome. While the falling heart undergoes metabolic reprogramming, the interorgan crosstalk regulating myocardial substrate preference in HFpEF remains elusive. We aimed to clarify the role of systemic and local ketogenesis in the pathogenesis of cardiac hypertrophy and HFpEF. Methods: A mouse model of HFpEF was employed using a high-fat diet combined with NG-Nitro-L-arginine methyl ester hydrochloride (L-NAME). Cardiac hypertrophy and systemic metabolic profiling including ketogenesis were evaluated. To dissect the role of site-specific ketogenesis, we generated inducible cardiomyocyte-specific ( Hmgcs2 ΔiCM ) and hepatocyte-specific ( Hmgcs2 ΔHep ) knockout mice of HMG-CoA synthase 2 ( Hmgcs2 ), deficient in the rate-limiting enzyme for ketogenesis. Cardiomyocyte -specific nuclei were isolated for transcriptomic (RNA-seq) and in vitro assays in H9C2 cells were used to elucidate molecular mechanisms. Results: The HFpEF model successfully exhibited diastolic dysfunction, impaired exercise capacity and cardiac hypertrophy with elevated circulating ketone body concentration. Myocardial metabolomics and snRNA-seq identified a profound metabolic shift characterized by the accumulation of long-chain fatty acids and Krebs cycle intermediates, coupled with the transcriptional downregulation of insulin signaling and fatty acid degradation pathways. Although circulating ketone body level was upregulated, Hmgcs2 ΔiCM mice showed no exacerbation of the HFpEF phenotype. In contrast, Hmgcs2 ΔHep mice exhibited significantly aggravated cardiac hypertrophy (HW/TL; Hmgcs2 flox : 7.41 ± 0.87: Hmgcs2 ΔHep : 8.29 ± 0.73; p = 0.0154). Mechanistically, hepatic ketogenesis was required to maintain circulating beta-hydroxybutyrate (BHB) levels, which directly modulated cardiomyocyte metabolism. BHB acted as a metabolic signal to dampen fatty acid overload and facilitate glucose utilization. Conclusions: Our study identifies a critical "liver-heart axis" where hepatic ketogenesis serves as an essential regulator of myocardial metabolic resilience. Impaired hepatic ketogenesis creates a metabolic mismatch that drives pathological cardiac remodeling. These findings highlight the liver as a therapeutic target within the CKM syndrome framework, suggesting that restoring the hepato-cardiac metabolic bridge may ameliorate HFpEF progression. What is New?: This study identifies a novel liver–adipose–heart axis that governs myocardial metabolic resilience during the development of heart failure with preserved ejection fraction (HFpEF). We demonstrate that while both the liver and heart upregulate ketogenesis under metabolic stress, only hepatic ketogenesis—and not cardiac-intrinsic ketogenesis—is essential for mitigating pathological cardiac remodeling. Mechanistically, liver-derived β -hydroxybutyrate acts as a critical endocrine signal that dampens fatty acid oxidation and facilitates myocardial glucose utilization. What Are the Clinical Implications?: Our findings highlight the liver as a central therapeutic target within the cardiovascular–kidney–metabolic (CKM) syndrome framework, where hepatic metabolic failure directly drives cardiac dysfunction. Restoring the hepato-cardiac metabolic bridge, through either hepatic-targeted therapies or ketone body supplementation, represents a promising strategy to enhance myocardial metabolic flexibility and ameliorate HfpEF in patients with multi-organ metabolic disorders.

  • Open Access

    Nonsteroidal mineralocorticoid receptor antagonist finerenone ameliorates cardiac hypertrophy with increasing glucocorticoid signaling sensitivity

    by Kei Morikawa, Yuichiro Arima, Takumi Nagakura, Yuqing Xu, Akira Fujiyama, Miho Kataoka, Shinsuke Hanatani, Yasushi Matsuzawa, Yasuhiro Izumiya, Eiichiro Yamamoto, et al.


  • Open Access

    Table S1 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion

    by Kosuke Toyoda, Jun-Ichirou Yasunaga, Takafumi Shichijo, Yuichiro Arima, Kenichi Tsujita, Azusa Tanaka, Tarig Salah, Wenyi Zhang, Osama Hussein, Miyu Sonoda, et al.

    Human cluster 2 genes whose H3K27me3 in TSS's was decreased.

  • Open Access

    Table S3 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion

    by Kosuke Toyoda, Jun-Ichirou Yasunaga, Takafumi Shichijo, Yuichiro Arima, Kenichi Tsujita, Azusa Tanaka, Tarig Salah, Wenyi Zhang, Osama Hussein, Miyu Sonoda, et al.

    Oligonucleotides used in this study.

  • Open Access

    Figure S3 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion

    by Kosuke Toyoda, Jun-Ichirou Yasunaga, Takafumi Shichijo, Yuichiro Arima, Kenichi Tsujita, Azusa Tanaka, Tarig Salah, Wenyi Zhang, Osama Hussein, Miyu Sonoda, et al.

    Regulation of TP73 by BATF3 and IRF4.

  • Open Access

    Figure S6 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion

    by Kosuke Toyoda, Jun-Ichirou Yasunaga, Takafumi Shichijo, Yuichiro Arima, Kenichi Tsujita, Azusa Tanaka, Tarig Salah, Wenyi Zhang, Osama Hussein, Miyu Sonoda, et al.

    Efficacy of the MCT1/4 inhibitor syrosingopine on ATL cells.